Drug or treatment

Anlotinib clinical trials

• 59Clinical trials
• 2New in 30 days
• 5Countries

Newest trials

All recruiting trials (59)

• Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma

  This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07917949

• Pucotenlimab and Anlotinib with Chemo Before Surgery for Early-Stage Triple-Negative Breast Cancer

  This study tests a combo of pucotenlimab, anlotinib, and nab-paclitaxel before surgery in adults with newly diagnosed, stage II-III triple-negative breast cancer that is PD-L1 known.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou · NCT07896668

• Anlotinib Plus PD-1 Inhibitor vs PD-1 Inhibitor Alone After Chemoimmunotherapy in Advanced ESCC

  This trial tests whether adding anlotinib to PD-1 inhibitor maintenance after initial chemoimmunotherapy helps people with advanced esophageal squamous cell carcinoma live longer without the cancer growing.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07863141

• Tislelizumab plus Anlotinib after chemoradiotherapy in limited-stage SCLC

  This phase II trial tests whether adding tislelizumab and anlotinib after chemoradiotherapy helps people with limited-stage small cell lung cancer stay cancer-free.

  Recruiting Phase 2 Yantai Yuhuangding Hospital · Yantai, Shandong · NCT07815223

• First-line combo therapy with anlotinib, benmelstobart, and HAIC for unresectable HCC

  This study tests whether adding benmelstobart and hepatic arterial infusion chemotherapy to anlotinib can help people with unresectable hepatocellular carcinoma respond to treatment as a first line.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07806292

• Anlotinib plus Bemocizumab as neoadjuvant therapy for ESCC

  This trial tests whether giving anlotinib with bemocizumab before surgery can improve how completely the tumor is removed and prevent recurrence in people with resectable esophageal squamous cell carcinoma.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07627347

• Neoadjuvant therapy with anlotinib and epirubicin for T4 sinonasal adenoid cystic carcinoma

  This trial tests whether giving a targeted drug (anlotinib) plus chemotherapy (epirubicin) before surgery helps patients with advanced sinonasal adenoid cystic carcinoma see better outcomes.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Beijing, Beijing Municipality and 4 other locations · NCT07616141

• First-line therapy for advanced TNBC with QL1706, plus anlotinib and nab-paclitaxel

  This study tests whether a combination of QL1706 with anlotinib and nab-paclitaxel can help people with newly diagnosed, advanced triple-negative breast cancer.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu · NCT07601178

• Sintilimab plus anlotinib and a taxane for recurrent or metastatic nasopharyngeal carcinoma

  This trial will test whether adding the PD‑1 drug sintilimab and the oral anti‑angiogenic anlotinib to a taxane chemotherapy helps adults with recurrent or metastatic nasopharyngeal carcinoma who have already failed platinum chemotherapy and/or prior anti‑PD‑1/PD‑L1 therapy.

  Recruiting Phase 2 Sun Yat-sen University · Zhuhai, Guangdong · NCT07581821

• Luvometinib plus Anlotinib in KRAS-mutated NSCLC

  This study tests whether the combination of luvometinib and anlotinib helps people with KRAS-mutated metastatic non-small cell lung cancer who have tried prior treatments.

  Recruiting Phase 2 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Shanghai, Shanghai Municipality · NCT07562581

• Benmelstobart plus anlotinib for advanced or inoperable alveolar soft part sarcoma

  This trial will test whether combining benmelstobart injections with anlotinib pills helps people aged 14 and older who have advanced or unresectable alveolar soft part sarcoma.

  Recruiting Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 14 other locations · NCT07548177

• Eribulin plus anlotinib for HER2‑negative recurrent or metastatic breast cancer after ADCs

  This trial tests whether combining eribulin and anlotinib helps people with HER2‑negative recurrent or metastatic breast cancer whose disease progressed after antibody‑drug conjugates.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou · NCT07520760

• Bemosubaiabimab plus anlotinib with radiotherapy and chemotherapy for oligometastatic esophageal cancer

  This trial tests whether adding bemosubaiabimab to anlotinib together with radiotherapy and chemotherapy helps people with oligometastatic esophageal squamous cell carcinoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07455019

• Combining anlotinib with whole-brain radiotherapy for SCLC brain metastases

  This trial will test whether adding the targeted drug anlotinib to whole-brain radiotherapy helps people with small cell lung cancer who have brain metastases.

  Recruiting Phase 3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07443397

• Anlotinib plus sintilimab as first treatment for advanced colorectal cancer without liver metastases

  This study will see if taking anlotinib together with sintilimab as the first treatment helps adults with advanced colorectal cancer that has spread outside the liver who cannot or choose not to have standard chemotherapy.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07398326

• Radiation with anlotinib for HER2-negative breast cancer brain metastases

  This trial tests whether adding the drug anlotinib to stereotactic or whole-brain radiotherapy (with a microtubule inhibitor) helps people with HER2-negative breast cancer that has spread to the brain.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing · NCT07396454

• Paclitaxel polymer micelles with gemcitabine and targeted drugs for advanced sarcoma

  This Phase 2 study tests whether combining a new paclitaxel formulation with gemcitabine and a targeted drug can help people with advanced or metastatic bone or soft tissue sarcoma that progressed after first-line chemotherapy.

  Recruiting Phase 2 Shanghai 6th People's Hospital · Shanghai, CH · NCT07359053

• Bemotuzumab with chemotherapy and anlotinib, then targeted radiotherapy for extensive-stage small cell lung cancer

  This phase 2 study tests whether a combination of bemotuzumab, chemotherapy, and anlotinib, followed by continued bemotuzumab and anlotinib with thoracic radiotherapy, can help untreated extensive-stage small cell lung cancer.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07358676

• Entinostat with or without anlotinib plus fulvestrant for HR-positive, HER2-negative advanced breast cancer after endocrine therapy

  This trial tests whether adding entinostat, with or without anlotinib, to fulvestrant helps women with HR+/HER2- advanced breast cancer whose disease progressed after endocrine therapy and CDK4/6 inhibitors.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Zhejiang, Hangzhou · NCT07330544

• QL1706 with chemotherapy and anlotinib for recurrent ovarian cancer

  This trial will test whether adding QL1706 to chemotherapy and anlotinib helps women with recurrent epithelial ovarian cancer respond better and delay disease progression.

  Recruiting Phase 2 Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Guangzhou, Guangdong · NCT07286240

• TQB2868 plus anlotinib with chemotherapy versus placebo plus chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma

  This trial will see if adding TQB2868 injection and anlotinib capsules to first-line chemotherapy helps adults with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer than chemotherapy with placebo.

  Recruiting at 2 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 70 other locations · NCT07165951

• Tislelizumab with Anlotinib and Nab-Paclitaxel before surgery for resectable NSCLC

  A group of adults with stage II–III non-small cell lung cancer is given tislelizumab plus anlotinib and nab-paclitaxel before surgery to see if the treatment helps shrink tumors and is safe.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT07089199

• Using Amlotinib to treat recurrent craniopharyngiomas

  This study is testing if the drug amlotinib can help people with recurring craniopharyngiomas feel better and live longer while keeping an eye on any side effects.

  Recruiting Phase 1/2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06970145

• Combining Furmonertinib and Anlotinib for Advanced Lung Cancer with Brain Metastasis

  This study is testing if combining two drugs, Furmonertinib and Anlotinib, can help people with advanced lung cancer that has spread to the brain feel better and live longer.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou · NCT06945705

• Treatment for metastatic nasopharyngeal carcinoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with advanced nasopharyngeal cancer live longer without their cancer getting worse.

  Recruiting Phase 1 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06886347

• Pre-surgery chemotherapy with anlotinib and benmelstobart for HR+/HER2- breast cancer

  This trial tests whether adding anlotinib and benmelstobart to pre-surgery chemotherapy helps people with hormone receptor–positive, HER2‑negative breast cancer achieve a complete response before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang and 2 other locations · NCT06874933

• Treatment for advanced nasopharyngeal carcinoma using targeted therapy and immunotherapy.

  This study is testing a new combination of targeted therapy and immunotherapy with chemotherapy to see if it helps people with advanced nasopharyngeal cancer live longer without their disease getting worse.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06851247

• Tislelizumab plus anlotinib as a second-line treatment for thymoma and thymic carcinoma

  This trial will test whether combining tislelizumab with anlotinib is safe and can control thymoma or thymic carcinoma in people whose cancer progressed after first-line chemotherapy (with or without immunotherapy).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06838910

• Combining TQB2868 injection, Anlotinib, and chemotherapy for treating metastatic pancreatic cancer

  This study is testing a new combination of TQB2868 injection, Anlotinib, and chemotherapy to see if it can help people with metastatic pancreatic cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Zhengzhou, Henan and 6 other locations · NCT06767813

• Combination treatment for advanced pancreatic cancer

  This study is testing a new combination treatment for advanced pancreatic cancer to see if it helps patients who haven't had treatment before.

  Recruiting Phase 1/2 Fujian Provincial Hospital · Fuzhou, Fujian and 3 other locations · NCT06761027

• Combination therapy using Anlotinib for HR+ metastatic breast cancer

  This study is testing a new combination treatment with anlotinib for women with hormone receptor-positive metastatic breast cancer who haven’t had success with other therapies.

  Recruiting Hunan Cancer Hospital · Changsha, Hunan · NCT06734533

• Combining penpulimab, anlotinib, and chemotherapy for esophageal cancer treatment

  This study is testing if a new combination of medications, including penpulimab and anlotinib, can improve treatment for people with advanced esophageal cancer before surgery.

  Recruiting Phase 2 Xijing Hospital · Xi'an, Shaan'xi · NCT06586242

• Combining Anlotinib with Doxorubicin and Radiotherapy for Soft Tissue Sarcoma Treatment

  This study is testing if combining a cancer drug called anlotinib with chemotherapy and radiation can help people with high-grade soft tissue sarcoma have better treatment results before surgery.

  Recruiting at 2 sites Phase 4 Guangdong Provincial People's Hospital · Guangzhou, Guangdong and 1 other locations · NCT06506838

• Combining SRT and Anlotinib for treating brain metastases from lung cancer

  This study is testing if combining a targeted cancer drug called Anlotinib with a type of focused radiation therapy can help patients with non-small cell lung cancer who have limited brain metastases and haven't responded to other treatments.

  Recruiting The First People's Hospital of Lianyungang · Lianyungang, Jiangsu · NCT06476093

• Short-course radiation then tislelizumab plus anlotinib before and after surgery for stage II–IIIA lung cancer

  This study will try short-course radiotherapy followed by the immune drug tislelizumab and the targeted drug anlotinib given before and after surgery for people with stage II–IIIA non-small cell lung cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06379087

• Combination treatment for advanced lung cancer with specific mutations

  This study is testing a new combination of two drugs to see if it can help people with advanced lung cancer who have certain genetic mutations live longer without their cancer getting worse.

  Recruiting Phase 2 Hunan Province Tumor Hospital · Changsha, Hunan · NCT06355609

• Neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma

  This study is testing two different treatment plans for people with advanced esophageal cancer to see which one works better and is safer before surgery.

  Recruiting Phase 2/3 Army Medical Center of PLA · Chongqing, None Selected · NCT06354530

• Anlotinib after surgery for non-pCR non-small cell lung cancer

  This will test whether taking anlotinib capsules after surgery helps people with stage IIA–IIIA non-small cell lung cancer who did not have a complete pathological response after preoperative chemo‑immunotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06352008

• Combination treatment for advanced lung cancer with specific mutations

  This study is testing a new combination of two drugs for people with advanced lung cancer who have specific genetic mutations to see if it helps them live longer without their cancer getting worse.

  Recruiting Phase 2 Hunan Province Tumor Hospital · Changsha, Hunan · NCT06348927

• Combining Anlotinib and Trastuzumab Deruxtecan for Advanced HER2-Low Breast Cancer

  This study is testing if combining two drugs, anlotinib and trastuzumab deruxtecan, can help people with advanced HER2-low breast cancer who have already had one round of chemotherapy.

  Recruiting Phase 1 Fudan University · Shanghai, Shanghai Municipality · NCT06331169

• Liposomal irinotecan plus anlotinib as a second-line treatment for recurrent small cell lung cancer

  This trial tests whether combining liposomal irinotecan with the oral drug anlotinib helps people whose small cell lung cancer came back within six months after platinum chemotherapy.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06258642

• Combining TQB2450 injection with Anlotinib and chemotherapy for advanced lung cancer

  This study is testing if adding a new injection called TQB2450 to Anlotinib and chemotherapy can help people with advanced lung cancer who haven't responded to earlier treatments.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Huizhou, Guangdong and 4 other locations · NCT06141226

• Combining almonertinib and anlotinib for advanced lung cancer treatment

  This study is testing a new combination of two drugs, almonertinib and anlotinib, to see if it can help people with advanced lung cancer who have certain genetic mutations.

  Recruiting Phase 3 Qianfoshan Hospital · Jinan, Shandong · NCT06043973

• Using Anlotinib capsules to treat advanced thyroid cancer

  This study is testing if Anlotinib capsules can help people with advanced thyroid cancer that doesn't respond to standard treatments feel better and have fewer side effects.

  Recruiting at 3 sites Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT05994365

• Combining Cadonilimab and Anlotinib for Advanced Soft Tissue Sarcoma

  This study is testing a new combination treatment of cadonilimab and anlotinib to see if it helps people with advanced soft tissue sarcoma who haven't had success with other treatments.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT05926700

• Combining TQB2450 with chemotherapy or anlotinib for treating non-small cell lung cancer

  This study is testing if adding a new drug called TQB2450 to chemotherapy or another treatment can help people with non-small cell lung cancer do better after surgery.

  Recruiting at 7 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 9 other locations · NCT05913089

• Combining Anlotinib and Penpulimab for Hepatocellular Carcinoma Treatment

  This study is testing if a new combination of two treatments can help prevent liver cancer from coming back in patients who are at high risk after surgery or other treatments.

  Recruiting at 47 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bengbu, Anhui and 66 other locations · NCT05862337

• Evaluating Anlotinib for Advanced Medullary Thyroid Cancer

  This study is testing whether Anlotinib can help people with advanced medullary thyroid cancer feel better and manage their disease more effectively.

  Recruiting at 15 sites Phase 4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 18 other locations · NCT05830500

• Combination treatment for recurrent cervical cancer

  This study is testing a new combination of treatments for people with recurrent cervical cancer to see if it helps them feel better and live longer.

  Recruiting Phase 2 Zhongnan Hospital · Wuhan, Hubei · NCT05817214

• Combination treatment for ctDNA positive gastric cancer

  This study is testing a new combination treatment for patients with a specific type of stomach cancer to see if it works better than the usual treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05494060

• Combining anlotinib and vinorelbine for HER2-negative advanced breast cancer

  This study is testing if combining two drugs, anlotinib and vinorelbine, can help women with advanced HER2-negative breast cancer who haven't had success with other treatments.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT05296577

• Combining Dacomitinib and Anlotinib for Advanced Lung Cancer Treatment

  This study is testing if combining two drugs, dacomitinib and anlotinib, can help people with advanced lung cancer that has a specific mutation feel better and improve their treatment results.

  Recruiting Phase 1/2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT05271916

• Combination of Anlotinib and TQB2450 for Esophageal Cancer Treatment

  This study is testing if combining two medications, Anlotinib and TQB2450, can help people with esophageal cancer stay cancer-free after surgery.

  Recruiting Phase 2 Jiangxi Provincial Cancer Hospital · Nanchang, Jiangxi · NCT05252078

• Combination of Penpulimab and Chemotherapy for Advanced Esophageal Cancer

  This study is testing if adding Anlotinib to Penpulimab and chemotherapy can help people with advanced esophageal cancer feel better compared to just using Penpulimab and chemotherapy alone.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT05214222

• Combining Sintilimab, Anlotinib, and Chemotherapy for Advanced Pleural Mesothelioma

  This study is testing a new combination of Sintilimab, Anlotinib, and chemotherapy to see if it helps people with advanced pleural mesothelioma who haven't had treatment before.

  Recruiting at 2 sites Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Taiyuan, Shanxi and 1 other locations · NCT05188859

• Preoperative intensity-modulated radiotherapy with concurrent anlotinib for localized extremity and trunk soft tissue sarcoma

  This test combines preoperative IMRT and the drug anlotinib to see if it improves outcomes for adults with primary soft tissue sarcoma of the arms, legs, or trunk.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT05167994

• Combining Anlotinib with Immune Checkpoint Inhibitors for Lung Cancer Treatment

  This study is testing whether combining a drug called Anlotinib with immune treatments can help people with advanced lung cancer who haven't responded to other therapies live longer without their cancer getting worse.

  Recruiting Phase 2/3 Hunan Province Tumor Hospital · Changsha, Hunan · NCT04322617

• Pemetrexed and carboplatin, with or without anlotinib, for advanced non-squamous NSCLC after osimertinib

  This trial tests whether adding anlotinib to pemetrexed plus carboplatin helps people with advanced non-squamous NSCLC whose cancer progressed on osimertinib.

  Recruiting Phase 2 Fudan University · Shenzhen, shenzhen · NCT04136535

• Phase 3 test of anlotinib (AL3818) versus dacarbazine in advanced alveolar soft part sarcoma, leiomyosarcoma, and synovial sarcoma

  This trial tests whether anlotinib (AL3818) helps adults with advanced alveolar soft part sarcoma, while earlier arms compared anlotinib to dacarbazine for leiomyosarcoma and synovial sarcoma that are no longer enrolling.

  Recruiting Phase 3 Advenchen Laboratories, LLC · Phoenix, Arizona and 23 other locations · NCT03016819

Quick answers

How many clinical trials of Anlotinib are recruiting right now?

59, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 5 countries. The most sites are in China (59 trials), Italy (1 trial), Spain (1 trial), United Kingdom (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 40, Phase 3: 5, Phase 1/2: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →